Showing results (301-310 of 311) with videos related to

Sort By:
Pageof 32
Nature|March 12, 2003
Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40Yasuaki Itoh, Yuji Kawamata, Masataka Harada, et al.
Mycoses|June 19, 2025
Risk Factors and Long-Term Prognosis for Coinfection of Nontuberculous Mycobacterial Pulmonary Disease and Chronic Pulmonary Aspergillosis: A Multicentre Observational Study in JapanYasuhiro Tanaka, Shotaro Ide, Takahiro Takazono, et al.
Cancer Immunology, Immunotherapy : CII|May 17, 2024
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patientsYutaka Shimazu, Junya Kanda, Yoshiyuki Onda, et al.
International Journal of Hematology|March 29, 2024
Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021)Hirohiko Shibayama, Mitsuhiro Itagaki, Hiroshi Handa, et al.
BMJ Open|June 14, 2022
Tadalafil treatment for fetuses with early-onset growth restriction: a protocol for a multicentre, randomised, placebo-controlled, double-blind phase II trial (TADAFER IIb)Shintaro Maki, Hiroaki Tanaka, Sho Takakura, et al.
Journal of Clinical Medicine|September 23, 2022
Evaluation of a Triage Checklist for Mild COVID-19 Outpatients in Predicting Subsequent Emergency Department Visits and Hospitalization during the Isolation Period: A Single-Center Retrospective StudyYasuhiro Tanaka, Kazuko Yamamoto, Shimpei Morimoto, et al.
Scientific Reports|March 29, 2023
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulinYutaka Shimazu, Junya Kanda, Satoru Kosugi, et al.
Therapeutic Advances in Hematology|December 19, 2022
Monocyte or white blood cell counts and β<sub>2</sub> microglobulin predict the durable efficacy of daratumumab with lenalidomideYutaka Shimazu, Junya Kanda, Hitomi Kaneko, et al.
Leukemia Research Reports|December 11, 2023
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma ForumAya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, et al.
European Journal of Haematology|September 9, 2025
Significance of Pre- and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core-Binding Factor Acute Myeloid LeukemiaChika Tokuda, Makoto Iwasaki, Junya Kanda, et al.
Pageof 32